封面
市場調查報告書
商品編碼
1732869

人類 DNA 疫苗市場 - 全球產業規模、佔有率、趨勢、機會及預測,依給藥途徑、應用、最終用戶、地區及競爭情況細分,2020-2030 年預測

Human DNA Vaccine Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Route of Administration, By Application, By End User, By Region & Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球人類 DNA 疫苗市場價值為 3.4544 億美元,預計到 2030 年將達到 5.2399 億美元,複合年成長率為 7.15%。受基因工程進步、醫療保健領域投資增加以及對尖端治療和預防解決方案的需求增加的推動,該市場正在經歷強勁成長。 DNA疫苗透過直接傳遞編碼特定抗原的工程質粒DNA來發揮作用,刺激精確的免疫反應。這些疫苗因其增強的安全性、更短的開發時間以及對廣泛疾病的適應性而脫穎而出。 DNA 疫苗市場處於充滿活力的疫苗產業中,在持續的技術突破、擴大的臨床應用和日益增強的全球健康優先事項的推動下,它將快速發展。符合監管趨勢並在交付技術方面進行創新的公司有望獲得顯著的競爭優勢。

市場概覽
預測期 2026-2030
2024年市場規模 3.4544億美元
2030年市場規模 5.2399億美元
2025-2030 年複合年成長率 7.15%
成長最快的領域 肌肉注射
最大的市場 北美洲

關鍵市場促進因素

傳染病和慢性病發生率上升

主要市場挑戰

有限的臨床成功和監管批准

主要市場趨勢

朝向基於平台的疫苗技術轉變

目錄

第 1 章:產品概述

第2章:研究方法

第3章:執行摘要

第4章:顧客之聲

第5章:人類DNA疫苗市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依給藥途徑(肌肉注射、皮下注射、皮內注射、其他)
    • 按應用(腫瘤學、結核病、愛滋病毒、其他)
    • 按最終用戶(醫院和診所、生物技術和製藥公司、學術和研究機構、其他)
    • 按地區
    • 按公司分類(2024)
  • 市場地圖

第6章:北美人類DNA疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美:國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章:歐洲人類DNA疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲:國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第8章:亞太人類DNA疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區:國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章:南美人類DNA疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲:國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章:中東和非洲人類DNA疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA:國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章:市場動態

  • 驅動程式
  • 挑戰

第 12 章:市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章:全球人類 DNA 疫苗市場:SWOT 分析

第 14 章:競爭格局

  • BOEHRINGER INGELHEIM GmbH (Merial)
  • ELI-LILLY (Novartis Animal Health)
  • Gene One Life Science
  • GEOVAX LABS, INC
  • Inovio Pharmaceuticals (VGX Animal Health)
  • Genexine, Inc.
  • VIATRIS INC. (Rottapharm Biotech)
  • Takara Holdings (Takara Bio)
  • ZOETIS INC. (Fort dodge Animal Health)
  • Zydus Lifesciences Limited

第 15 章:策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 14276

The Global Human DNA Vaccine Market was valued at USD 345.44 million in 2024 and is projected to reach USD 523.99 million by 2030, growing at a CAGR of 7.15%. This market is undergoing robust growth fueled by advancements in genetic engineering, increased investment in the healthcare sector, and heightened demand for cutting-edge therapeutic and preventive solutions. DNA vaccines operate through the direct delivery of engineered plasmid DNA encoding specific antigens, stimulating precise immune responses. These vaccines stand out for their enhanced safety profile, shorter development timelines, and adaptability across a broad spectrum of diseases. Positioned within the dynamic vaccine industry, the DNA vaccine market is poised for rapid evolution driven by continuous technological breakthroughs, expanded clinical applications, and heightened global health priorities. Companies that align with regulatory trends and innovate in delivery technologies are expected to gain significant competitive advantages.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 345.44 Million
Market Size 2030USD 523.99 Million
CAGR 2025-20307.15%
Fastest Growing SegmentIntramuscular
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Infectious and Chronic Diseases

The escalating occurrence of both infectious and chronic diseases is a critical driver for the Global Human DNA Vaccine Market. In 2021, approximately 18 million people died prematurely from noncommunicable diseases (NCDs), with 82% of these deaths occurring in low- and middle-income countries (LMICs), underscoring the disproportionate impact on economically disadvantaged regions. Furthermore, LMICs accounted for 73% of all NCD-related deaths globally. This significant health burden amplifies the need for innovative vaccination approaches like DNA vaccines, which are gaining momentum due to their unique benefits. Notably, in 2023, about 1.3 million people contracted HIV worldwide, a 39% reduction in new cases from 2010, indicating a global infection rate of 0.17 per 1,000 uninfected individuals. As diseases such as HIV, Hepatitis, Tuberculosis, HPV, COVID-19, Zika, and Ebola continue to challenge public health systems, DNA vaccines offer scalable, adaptable, and long-lasting immune protection-traits that are increasingly in demand globally.

Key Market Challenges

Limited Clinical Success and Regulatory Approvals

Despite encouraging outcomes in preclinical stages, human DNA vaccines face challenges in achieving strong clinical efficacy. A primary obstacle is their lower immunogenicity in humans when compared to traditional vaccine types, which often leads to suboptimal immune responses in clinical settings-especially when conventional administration methods are used. Consequently, regulatory approval for human use remains limited, with most authorizations to date focused on veterinary applications. Although the pandemic has accelerated interest in DNA vaccines for humans, regulatory bodies continue to require comprehensive data on long-term safety and efficacy. These stringent and often uncertain regulatory demands present a substantial hurdle, particularly for smaller biotech firms, thereby slowing commercial progress and investment in the field.

Key Market Trends

Shift Toward Platform-Based Vaccine Technologies

The vaccine sector is witnessing a strong trend toward platform-based technologies, which leverage a unified system for developing multiple vaccines. DNA vaccine platforms exemplify this model. By standardizing delivery mechanisms, production processes, and clinical trial protocols, these platforms significantly cut down on development time and costs. They also enable rapid responses to emergent health threats, supporting quicker vaccine rollouts. Pharmaceutical companies and investors are increasingly attracted to this scalable framework, which not only fosters efficient product pipelines but also strengthens pandemic preparedness strategies. These systems support diverse disease applications, enhance public-private collaborations, and draw funding from global health stakeholders.

Key Market Players

  • BOEHRINGER INGELHEIM GmbH (Merial)
  • ELI-LILLY (Novartis Animal Health)
  • Gene One Life Science
  • GEOVAX LABS, INC
  • Inovio Pharmaceuticals (VGX Animal Health)
  • Genexine, Inc.
  • VIATRIS INC. (Rottapharm Biotech)
  • Takara Holdings (Takara Bio)
  • ZOETIS INC. (Fort dodge Animal Health)
  • Zydus Lifesciences Limited

Report Scope:

In this report, the Global Human DNA Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human DNA Vaccine Market, By Route of Administration:

  • Intramuscular
  • Subcutaneous
  • Intradermal
  • Others

Human DNA Vaccine Market, By Application:

  • Oncology
  • Tuberculosis
  • HIV
  • Others

Human DNA Vaccine Market, By End User:

  • Hospitals & Clinics
  • Biotechnology & Pharmaceutical Companies
  • Academic & Research Institutions
  • Others

Human DNA Vaccine Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human DNA Vaccine Market.

Available Customizations:

Global Human DNA Vaccine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Human DNA Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others)
    • 5.2.2. By Application (Oncology, Tuberculosis, HIV, Others)
    • 5.2.3. By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Human DNA Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Route of Administration
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Human DNA Vaccine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Route of Administration
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Human DNA Vaccine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Route of Administration
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Human DNA Vaccine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Route of Administration
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Human DNA Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Route of Administration
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Human DNA Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Route of Administration
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Human DNA Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Route of Administration
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. Italy Human DNA Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Route of Administration
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. France Human DNA Vaccine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Route of Administration
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Human DNA Vaccine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Route of Administration
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific Human DNA Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Route of Administration
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Human DNA Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Route of Administration
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Human DNA Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Route of Administration
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Human DNA Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Route of Administration
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Human DNA Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Route of Administration
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Human DNA Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Route of Administration
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America Human DNA Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Route of Administration
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Human DNA Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Route of Administration
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Human DNA Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Route of Administration
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Human DNA Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Route of Administration
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Human DNA Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Route of Administration
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Human DNA Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Route of Administration
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Human DNA Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Route of Administration
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Human DNA Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Route of Administration
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Human DNA Vaccine Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. BOEHRINGER INGELHEIM GmbH (Merial)
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. ELI-LILLY (Novartis Animal Health)
  • 14.3. Gene One Life Science
  • 14.4. GEOVAX LABS, INC
  • 14.5. Inovio Pharmaceuticals (VGX Animal Health)
  • 14.6. Genexine, Inc.
  • 14.7. VIATRIS INC. (Rottapharm Biotech)
  • 14.8. Takara Holdings (Takara Bio)
  • 14.9. ZOETIS INC. (Fort dodge Animal Health)
  • 14.10.Zydus Lifesciences Limited

15. Strategic Recommendations

16. About Us & Disclaimer